Table 1 Sociodemographic and clinical characteristics of the study group (n = 60)
Sociodemographic variable | |
Age [mean years ± SD] | 69.1 ± 10.4 |
Gender | |
Female | 20 (33.3%) |
Male | 40 (66.7%) |
Marital Status | |
Partner | 38 (63.3%) |
Single | 13 (21.7%) |
Widowhood | 9 (15%) |
Level of education | |
Primary education | 26 (43.3%) |
Secondary education | 26 (43.3%) |
University degree | 8 (13.3%) |
Cohabitation | |
Live accompanied/independent | 38 (63.3%) |
Live accompanied/caregiver | 8 (13.3%) |
Live alone/independent | 14 (23.3%) |
Clinical variables | |
Trial phase | |
Phase 1 | 13 (21.7%) |
Phase 2 | 28 (46.7%) |
Phase 3 | 19 (31.7%) |
Tumour type | |
Colo-rectal | 6 (10%) |
Esophagogastric | 2 (3.3%) |
Genitourinary | 27 (45%) |
Breast | 5 (8.3%) |
Otorhinolaryngology | 1 (1.7%) |
Lung | 18 (30%) |
Skin | 1 (1.7%) |
Tumour stage | |
Stage 2 | 11 (18.3%) |
Stage 3 | 6 (10%) |
Stage 4 | 43 (71.7%) |
Comorbidities | |
Yes | 59 (98.3%) |
No | 1 (1.7%) |
Nº of Comorbidities (Abbreviated Charlson index) | |
No comorbidity | 5 (8.3%) |
Low comorbidity | 18 (30%) |
High comorbidity | 37 (61.7%) |
Type of comorbidity | |
Cardiovascular disease | 42 (70%) |
Musculoskeletal diseases | 32 (53.3%) |
Respiratory diseases | 26 (43.3%) |
Nervous system diseases | 23 (38.3%) |
Excretory diseases | 21 (35%) |
Digestive diseases | 20 (33.3%) |
Endocrine diseases | 15 (25%) |
Reproductive diseases | 13 (21.7%) |
Immunological diseases | 10 (16.7%) |
Skin diseases | 5 (8.3%) |
Lymphatic diseases | 2 (3.3%) |
Trial treatment | |
Chemotherapy | 11 (18.3%) |
Chemo-immunotherapy | 28 (46.7%) |
Immunotherapy | 9 (15%) |
Targeted therapies | 3 (5%) |
Hormonotherapy | 9 (15%) |
Nº of patients tested against COVID-19 | |
Symptomatic | 5 (8.3%) |
Asymptomatic | 55 (91.7%) |
Positive COVID tests | 0 (0%) |
Negative COVID tests | 5 (8.3%) |